H.C. Wainwright analyst Robert Burns assumed coverage of Elicio Therapeutics with a Buy rating and $12 price target. Elicio is developing novel cancer vaccines to address malignancies involving tumors carrying mutations in well-known oncogenes, including Kirsten rat sarcoma, the analyst tells investors in a research note. The firm says the company’s initial clinical data appears promising.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELTX:
- Elicio Therapeutics assumed with a Perform at Oppenheimer
- Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
- Angion Biomedica Corp trading resumes
- Angion Biomedica Corp trading halted, volatility trading pause
- Elicio Therapeutics receives $2.6M grant for two therapeutic cancer vaccines
